PIH31 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

Value in Health ◽

10.1016/j.jval.2019.04.831 ◽

2019 ◽

Vol 22 ◽

pp. S187-S188

Author(s):

D. Xiao ◽

S. Zhu ◽

W. Sun ◽

J. Xuan

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma

Liver International ◽

10.1111/liv.14257 ◽

2019 ◽

Vol 39 (12) ◽

pp. 2408-2416 ◽

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

David Hutton ◽

Guiqi Zhu ◽

Qiuji Wu ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

P-259 Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2020.04.341 ◽

2020 ◽

Vol 31 ◽

pp. S174

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

I. Wong ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Cancer Management and Research ◽

10.2147/cmar.s335515 ◽

2021 ◽

Vol Volume 13 ◽

pp. 8219-8230

Author(s):

Ying-Tao Lin ◽

Ying Chen ◽

Tian-Xiu Liu ◽

Fang Kuang ◽

Ping Huang

Keyword(s):

Squamous Cell Carcinoma ◽

Cost Effectiveness ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

A Cost-Effectiveness Analysis of Abatacept, Tocilizumab, And Tnf-Inhibitor Compared With Rituximab As A Second-Line Therapy For Treatment of Rheumatoid Arthritis

Value in Health ◽

10.1016/j.jval.2016.09.1110 ◽

2016 ◽

Vol 19 (7) ◽

pp. A538

Author(s):

S Huoponen ◽

KJ Aaltonen ◽

JT Joensuu ◽

J Rutanen ◽

H Relas ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Tnf Inhibitor ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States

Diabetes Obesity and Metabolism ◽

10.1111/dom.14268 ◽

2020 ◽

Author(s):

Odette Reifsnider ◽

Anuraag Kansal ◽

Pratik Pimple ◽

Valerie Aponte‐Ribero ◽

Sarah Brand ◽

...

Keyword(s):

United States ◽

Type 2 Diabetes ◽

Cost Effectiveness ◽

The United States ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China

Clinical Drug Investigation ◽

10.1007/s40261-021-01035-4 ◽

2021 ◽

Author(s):

Huahua Zhang ◽

Yandong Zhang ◽

Chaonan Huang ◽

Jiangfeng Wang

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Trastuzumab Emtansine ◽

Second Line ◽

Her2 Positive ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy ◽

Positive Breast Cancer

Download Full-text

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

BMC Gastroenterology ◽

10.1186/s12876-020-01241-y ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Maximilian Sieg ◽

Michael Hartmann ◽

Utz Settmacher ◽

Habibollah Arefian

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

The United States ◽

Advanced Hepatocellular Carcinoma ◽

Second Line ◽

Second Line Therapy ◽

Comparative Cost ◽

Download Full-text

PCN177 OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA

Value in Health ◽

10.1016/j.jval.2020.04.1658 ◽

2020 ◽

Vol 23 ◽

pp. S54

Author(s):

J. Zhou ◽

G. Jiang

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Egfr Mutation ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data

Journal of Medical Economics ◽

10.1080/13696998.2016.1261032 ◽

2016 ◽

Vol 20 (4) ◽

pp. 328-336 ◽

Author(s):

Nanxin Li ◽

Xi Yang ◽

Liangyi Fan ◽

Todor Totev ◽

Annie Guerin ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Philadelphia Chromosome ◽

Chronic Phase ◽

Second Line ◽

Real World Data ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma

JAMA Network Open ◽

10.1001/jamanetworkopen.2020.33761 ◽

2021 ◽

Vol 4 (1) ◽

pp. e2033761 ◽

Author(s):

Chi-leung Chiang ◽

Sik-kwan Chan ◽

Shing-fung Lee ◽

Irene Oi-ling Wong ◽

Horace Cheuk-wai Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text